The CHS advocates for access to a secure supply of the safest and most efficacious therapies for the treatment of inherited bleeding disorders.
Canadian Blood Services Board appointments
Blood Injury Compensation Scheme
Inhibitor rates related to treatment product in previously untreated patients:Statement from the WFH
Submissions on the funding of extended half‐life factor concentrates
Eloctate™ and Alprolix™, extended half-life factor VIII and factor IX for the treatment of hemophilia A and B, are approved by Health Canada. The Canadian Hemophilia Society submitted its recommendations concerning reimbursement in 2014. In 2016, both Canadian Blood Services and Héma-Québec added the two products to the list of those that could be reimbursed through their blood system budgets.